These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3106756)

  • 1. Effects of CS-514 on serum lipoprotein lipid and apolipoprotein levels in patients with familial hypercholesterolemia.
    Mabuchi H; Kamon N; Fujita H; Michishita I; Takeda M; Kajinami K; Itoh H; Wakasugi T; Takeda R
    Metabolism; 1987 May; 36(5):475-9. PubMed ID: 3106756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of CS-514 on plasma lipids and lipoprotein composition in hypercholesterolemic subjects.
    Yoshino G; Kazumi T; Iwai M; Iwatani I; Matsuba K; Kasama T; Matsushita M; Otsuki M; Baba S
    Atherosclerosis; 1988 Jun; 71(2-3):95-101. PubMed ID: 3135814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of CS-514 (eptastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipid and apolipoprotein levels in heterozygous familial hypercholesterolemic patients treated by low density lipoprotein (LDL)-apheresis.
    Mabuchi H; Fujita H; Michishita I; Takeda M; Kajinami K; Koizumi J; Takeda R; Takegoshi T; Wakasugi T; Ueda K
    Atherosclerosis; 1988 Aug; 72(2-3):183-8. PubMed ID: 3145745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition.
    Bard JM; Parra HJ; Douste-Blazy P; Fruchart JC
    Metabolism; 1990 Mar; 39(3):269-73. PubMed ID: 2106607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of CS-514 on serum lipids and apolipoproteins in hypercholesterolemic subjects.
    Nakaya N; Homma Y; Tamachi H; Shigematsu H; Hata Y; Goto Y
    JAMA; 1987 Jun; 257(22):3088-93. PubMed ID: 3108527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.
    Franceschini G; Sirtori M; Vaccarino V; Gianfranceschi G; Chiesa G; Sirtori CR
    J Lab Clin Med; 1989 Sep; 114(3):250-9. PubMed ID: 2504855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of CS-514, a new inhibitor of HMG CoA reductase, on plasma lipids, lipoproteins and apoproteins in patients with primary hypercholesterolemia.
    Kazumi T; Yoshino G; Kasama T; Iwatani I; Iwai M; Morita S; Baba S
    Horm Metab Res; 1986 Sep; 18(9):654-5. PubMed ID: 3096862
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia.
    Mabuchi H; Haba T; Tatami R; Miyamoto S; Sakai Y; Wakasugi T; Watanabe A; Koizumi J; Takeda R
    N Engl J Med; 1981 Aug; 305(9):478-82. PubMed ID: 7254297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of low-density lipoprotein receptors as estimated from concentrations of apolipoprotein B and C-II in serum.
    Ito H; Naito C; Hayashi H; Kawamura M
    Clin Chem; 1988 Nov; 34(11):2224-7. PubMed ID: 3141083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of familial hypercholesterolaemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels.
    Wiklund O; Angelin B; Fager G; Eriksson M; Olofsson SO; Berglund L; Lindén T; Sjöberg A; Bondjers G
    J Intern Med; 1990 Sep; 228(3):241-7. PubMed ID: 2119417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of colestipol hydrochloride on serum lipoprotein lipid and apolipoprotein B and A-I concentrations in children heterozygous for familial hypercholesterolemia.
    Groot PH; Dijkhuis-Stoffelsma R; Grose WF; Ambagtsheer JJ; Fernandes J
    Acta Paediatr Scand; 1983 Jan; 72(1):81-5. PubMed ID: 6407278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of CS-514, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on lipoprotein and apolipoprotein in plasma of hypercholesterolemic diabetics.
    Yoshino G; Kazumi T; Kasama T; Iwatani I; Iwai M; Inui A; Otsuki M; Baba S
    Diabetes Res Clin Pract; 1986 Jun; 2(3):179-81. PubMed ID: 3091343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of mRNA for low-density lipoprotein receptors in heterozygous Watanabe heritable hyperlipidemic rabbits treated with CS-514 (Pravastatin) and cholestyramine.
    Kume N; Kita T; Mikami A; Yokode M; Ishii K; Nagano Y; Kawai C
    Circulation; 1989 May; 79(5):1084-90. PubMed ID: 2496935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of lovastatin alone and in combination with cholestyramine on serum lipids and apolipoproteins in heterozygotes for familial hypercholesterolemia.
    Leren TP; Hjermann I; Berg K; Leren P; Foss OP; Viksmoen L
    Atherosclerosis; 1988 Oct; 73(2-3):135-41. PubMed ID: 3056429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term treatment of hypercholesterolemic non-insulin dependent diabetics (NIDDM) with pravastatin (CS-514).
    Yoshino G; Kazumi T; Iwai M; Matsushita M; Matsuba K; Uenoyama R; Iwatani I; Baba S
    Atherosclerosis; 1989 Jan; 75(1):67-72. PubMed ID: 2495012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose effect of simvastatin (MK-733) on serum lipids, lipoproteins, and apolipoproteins in patients with hypercholesterolemia.
    Saku K; Sasaki J; Arakawa K
    Clin Ther; 1989; 11(2):247-57. PubMed ID: 2736571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum lipid and apolipoprotein A and B levels in familial hypercholesterolemia.
    Craig IH; Poulis P; Hill G
    Aust N Z J Med; 1983 Jun; 13(3):241-6. PubMed ID: 6579937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine.
    Mabuchi H; Sakai T; Sakai Y; Yoshimura A; Watanabe A; Wakasugi T; Koizumi J; Takeda R
    N Engl J Med; 1983 Mar; 308(11):609-13. PubMed ID: 6828091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pravastatin on serum lipids, apolipoproteins and lipoprotein (a) in patients with non-insulin dependent diabetes mellitus.
    Umeda F; Watanabe J; Inoue K; Hisatomi A; Mimura K; Yamauchi T; Sako Y; Kunisaki M; Tajiri Y; Nawata H
    Endocrinol Jpn; 1992 Feb; 39(1):45-50. PubMed ID: 1535040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of pravastatin in relation to low density lipoprotein receptor activity.
    Hayashi H; Naito C; Ito H; Kawamura M; Miyazaki S
    Curr Med Res Opin; 1990; 12(2):100-7. PubMed ID: 2118022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.